Research Article

Synthesis and In Vitro Evaluation of Novel Nortropane Derivatives as Potential Radiotracers for Muscarinic M$_2$ Receptors

Remco J. J. Knol,$^{1}$ Jan C. van den Bos,$^{2,3}$ Anton G. M. Janssen,$^{3}$ Kora de Bruin,$^{4}$ Berthe L. F. van Eck-Smit,$^{4}$ and Jan Booij$^{4}$

$^1$Department of Nuclear Medicine, Medical Center Alkmaar, Wilhelminalaan 12, 1815 JD Alkmaar, The Netherlands
$^2$Department of Organic Chemistry, Eindhoven University of Technology, Den Dolech 2, 5600 MB Eindhoven, The Netherlands
$^3$GE Healthcare, Cygne Center, De Rondom 8, 5612 AP Eindhoven, The Netherlands
$^4$Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Correspondence should be addressed to Remco J. J. Knol, r.j.j.knol@mca.nl

Received 24 November 2010; Revised 3 March 2011; Accepted 25 March 2011

Academic Editor: Guy Bormans

Copyright © 2011 Remco J. J. Knol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disturbances of the cerebral cholinergic neurotransmitter system are present in neurodegenerative disorders. SPECT or PET imaging, using radiotracers that selectively target muscarinic receptor subtypes, may be of value for in vivo evaluation of such conditions. $^6$β-acetoxynortropane, a potent muscarinic M$_2$ receptor agonist, has previously demonstrated nanomolar affinity and high selectivity for this receptor. Based on this compound we synthesized four nortropane derivatives that are potentially suitable for SPECT imaging of the M$_2$ receptor. $^6$β-acetoxynortropane and the novel derivatives were tested in vitro for affinity to the muscarinic M$_1$−3 receptors. The original $^6$β-acetoxynortropane displayed high affinity ($K_i = 70–90$ nM) to M$_2$ receptors and showed good selectivity ratios to the M$_1$ (65-fold ratio) and the M$_3$ (70-fold ratio) receptors. All new derivatives showed reduced affinity to the M$_2$ subtype and loss of subtype selectivity. It is therefore concluded that the newly synthesized derivatives are not suitable for human SPECT imaging of M$_2$ receptors.

1. Introduction

Central cholinergic disturbances are present in many neuropsychiatric and neurodegenerative diseases. In various forms of dementia, such as Alzheimer’s dementia (AD) or Lewy body dementia, cholinergic deficits in the brain [1, 2] are associated with cognitive decline [3–5] and are thought to precede clinical symptoms.

The majority of the cholinergic deficits in these diseases arise from degenerative events in basal forebrain regions such as the nucleus basalis of Meynert [6, 7], which provides the cholinergic input of the cerebral cortex. In degenerative diseases such as AD, disruption of basal cholinergic forebrain projections leads to a presynaptic cholinergic defect in cortical brain areas [1, 8]. Being part of a family of five muscarinic receptor subtypes, the muscarinic M$_2$ receptor is located predominantly presynaptically [9] and is consequently a potential target for the evaluation of the integrity of the cholinergic neurotransmitter system by molecular imaging.

In vivo assessment of the central cholinergic system in patients suffering from dementia by means of positron emission tomography (PET) or single photon emission computed tomography (SPECT) may be of value for early diagnosis or monitoring of such diseases, to predict response to cholinergic therapies (such as acetylcholinesterase inhibitors) or to evaluate effects of experimental drugs. Molecular imaging of the cholinergic system of the brain requires radiotracers that ideally selectively target specific neuroreceptors of this neurotransmitter system, such as the muscarinic M$_2$ receptor.

Many attempts have been made to develop muscarinic receptor subtype selective radiotracers [10–12]. Currently, amongst the most promising of these potential tracers is $[^{18}$F]FP-TZTP [10, 13, 14], which has selectivity for the
derivatives as potential radiotracers for use in SPECT imaging of muscarinic M2 receptors [27], and radiolabeled derivatives reported to be a potent and highly selective agonist for the M2 receptor subtype is limited. Accordingly, a bromophenyl ring was introduced at the β-position. First, the 6-hydroxyfunction of tropinone (2) was protected as tert-butylimidethylsilylethyl. With a Grignard reaction 4-bromophenyl was introduced at the C3 of the tropinone. According to the signal of the C6α-H in the proton NMR spectrum, only the isomer with the 4-bromophenyl in the equatorial position had been formed. Desilylation followed by acetylation yielded 3β-(4-bromphenyl)-6β-acetoxy-N-benzyl nortropinone (9).

The benzyl group was removed by hydrogenation, but simultaneously also the bromo substituent was removed to result in 3a-hydroxy-3β-phenyl-6β-acetoxy-nortropinone (10b). In one occasion also the 3β-phenyl-6β-acetoxy-nortropinone (10a) was isolated, presumably due to the presence of a small amount of acid.

Relative binding affinity and selectivity ratios of the various nortropane derivatives for the M₁–M₃ receptors were determined by competitive binding assays against [3H]N-methylscopolamine ([3H]NMS, Perkin Elmer, Waltham, USA; specific activity 78 Ci (2886 GBq)/nmol). Assays were performed on membrane suspensions from CHO cells expressing either the recombinant human muscarinic M₁, M₂, or the M₃ receptor subtype (Perkin Elmer, Waltham, USA) [25].

In the competitive binding assays, incubation buffer contained 50 mM TRIS-HCl, 10 mM MgCl₂, and 1 mM EDTA (pH 7.4 at 4°C). The assays were incubated during 60 min (M₁ or M₂ receptor subtypes) or 120 min (M₃ receptor subtypes) at 27°C. Nonspecific binding was determined using atropine as a competitor in a concentration of 1 μM.

In the first series of competitive binding assays, the 6β-4′-iodobenzyl ether (5b) and the 6β-4′-iodobenzoate ester (5c) of 6β-nortropinol, as well as the lead compound 6β-acetoxynortropane (5a), were tested. Protein concentrations for undiluted receptor subtype suspensions were 1.2 mg/mL (M₁), 4.3 mg/mL (M₂), and 2.0 mg/mL (M₃). Aliquots (n = 3) of diluted membranes (factor 1 : 100) containing the M₁–M₃ receptor subtypes were incubated in a total volume of 540 μL containing 500 μL diluted membranes, 20 μL [3H]NMS, and 20 μL of the nortropanes in increasing concentrations. The [3H]NMS was used in a final concentration of 0.2 nM for the M₁ and M₂ assays and 0.09 nM for the M₃ assays. The equilibrium dissociation constants in nM of [3H]NMS for the three receptor subtypes, provided by the manufacturer, were 0.15 (M₁), 0.19 (M₂), and 0.08 (M₃). Final competitor concentrations ranged from 1.0 · 10⁻¹⁰ M to 1.0 · 10⁻⁴ M. After incubation, the reaction was rapidly terminated by vacuum filtration over GF/C glass fiber filters, presoaked in 0.3% polyethyleneimine (Sigma-Aldrich, Munich, Germany), and washed 5 times with 1 mL of ice-cold buffer. Filters were placed in vials with 10 mL of scintillation fluid (Ultima Gold, Perkin Elmer, Waltham, USA) and counted in a liquid scintillation counter (Tri-Carb 2900 TR Liquid Scintillation Analyzer, Packard. Software version: 3100).

In the second series of competitive binding assays, derivative 10a and 10b and the lead compound 6β-acetoxynortropane (5a) were tested. In this series, the protein

2. Material and Methods

Two nortropane analogues with an iodine containing moiety on the 6β-position have been synthesized. The tropinone skeleton was formed in a single-step multicomponent reaction in analogy to the classical Robinson tropinone synthesis [28, 29], as displayed in Figure 1. The resulting tropinone was reduced under Wolff-Kishner conditions to give 6-hydroxy-N-benzyl nortropinone (3). Alkylation or acetylation of the hydroxyl function of 3 resulted in 4a–c, which were debenzylated in two steps [29, 30] to provide the previously described 6β-acetoxynortropane (5a), and its iodinated analogues, the 6β-4′-iodobenzyl ether (5b) or the 6β-4′-iodobenzoate ester (5c) of 6β-nortropinol, respectively.
Figure 1: Reagents and conditions: (i) NH₂NH₂, NaOH; (ii) Ac₂O, pyridine; (iii) 4-iodobenzyl bromide, DMF; (iv) 4-iodobenzoyl chloride, DMAP, Et₃N, CH₂Cl₂; (v) α-chloroethyl chloroformate, Toluene; (vi) MeOH; (vii) TBDMSI, DMAP, Et₃N, DMF; (viii) Mg, 1,4-dibromobenzene, THF; (ix) HCl (2 M), THF, EtOH (1/1/1); (x) Ac₂O, pyridine; (xi) H₂, Pd/C. Variants 4a–c: R (a) CH₃CO, (b) p-IPhCH₂, and (c) p-IPhCO.
concentrations for undiluted receptor subtype suspensions were 0.6 mg/mL (M₁), 7.5 mg/mL (M₂), and 1.5 mg/mL (M₃). Aliquots (n = 4) of diluted membranes (factor 1:30) containing the M₁, M₂, or M₃ receptor subtype were incubated on a microplate in volumes of 190 μL containing 150 μL of undiluted membranes, 20 μL of [³H]NMS, and 20 μL of the nortropinanes in increasing concentrations. In these assays, the [³H]NMS was used in a final concentration of 0.13 nM for the M₁ and M₂ assays and 0.065 nM for the M₃ assays. The Kᵋ in nM of [³H]NMS in these experiments were as stated above. Final competitor concentrations ranged from 1.0·10⁻¹⁰ M to 1.0·10⁻⁵ M. After incubation, the assays were filtered over UniFilter GF/C filter plates, presoaked in 0.3% polyethylenimine (Sigma-Aldrich, Munich, Germany), and washed 9 times with 200 μL of ice-cold buffer. 30 μL of scintillation fluid (MicroScint, Perkin Elmer, Waltham, USA) was added, and the filter plates were counted in a liquid scintillation counter (TopCount 5.0 Liquid Scintillation Analyzer, Perkin Elmer, Waltham, USA). For each competitor, the inhibition constant (Kᵋ) was calculated from the EC₅₀ for the muscarinic M₁, M₂, and M₃ subtypes with nonlinear regression curve fitting using Graphpad Prism (version 3.02), relative to the Kᵋ of [³H]NMS as provided by the manufacturer.

3. Results

In Figure 2, the results of the competitive binding experiments are displayed. The affinity of 6β-acetoxynortropane, relative to [³H]NMS, for the muscarinic M₂ receptor subtype proved to be high in both experiments. In the first experiment the Kᵋ of 6β-acetoxynortropane was determined as 88.1 ± 23.8 nM (average ± SD; n = 3) and in the second experiment as 71.6 ± 4.8 nM (average ± SD; n = 4). In our experiments, selectivity ratios of the compound for the M₂ over M₁ or M₁ receptor subtype proved to be approximately 65 and 70, respectively.

The 6β-4’-iodobenzyl ether of 6β-nortropinol (5b) performed substantially less than 6β-acetoxynortropane and displayed a Kᵋ of only 3.0 ± 0.7 μM, while selectivity for the M₂ receptor was lost. The selectivity ratios of this derivative for the M₂ over the M₁ and M₃ receptors of the compound were determined as 0.1 and 0.2, respectively.

The 6β-4’-iodobenzoate ester of 6β-nortropinol (5c) also performed less than 6β-acetoxynortropane, and a Kᵋ of 6.8 ± 1.5 μM was estimated for the M₂ receptor, while selectivity ratios over the M₁ and M₃ receptor, were determined as 0.6 and 2.0, respectively.

The second series of experiments (Figure 2), using 3β-phenyl-6β-acetoxynortropane (10a) and 3α-hydroxy-3β-phenyl-6β-acetoxynortropane (10b) as competitors, likewise showed weak affinity for muscarinic receptors, and small competitive effects to the binding of [³H]NMS were only detected at the highest concentration of the tested range. The affinity for the muscarinic receptors could therefore not be assessed for these two derivatives.

4. Discussion

In the present study, we have synthesized derivatives that are based on 6β-acetoxynortropane, a tropane alkaloid described by Pei and coworkers, which was shown to be a muscarinic agonist with high affinity to muscarinic M₂ receptor subtypes, but lower affinity to other muscarinic receptor subtypes [27]. Due to the apparent selectivity of 6β-acetoxynortropane for the M₂ receptor, the compound may be of interest for use as a muscarinic receptor radiotracer.

Two analogues of the tracer were synthesized in which the acetyl ester moiety on the 6β-position was replaced by either 4’-iodobenzyl ether (5b) or a 4’-iodobenzoate ester (5c). The competitive binding assays demonstrated that the substitution on the 6β-position of the tropane skeleton had shifted the affinity from the nanomolar range to the micromolar range and that the selectivity of the alkaloid for the M₂ receptor subtype was lost. Therefore, two other analogues were synthesized retaining the 6β-acetoxy function, with substitution of a phenyl moiety on the 3β-position of the tropane skeleton: 3β-phenyl-6β-acetoxynortropane (10a) and 3α-hydroxy-3β-phenyl-6β-acetoxynortropane (10b). Unfortunately, these derivatives demonstrated even less favorable affinity for the three tested muscarinic receptor subtypes.

The challenge of the present study was to create a derivative of 6β-acetoxynortropane that is suitable for (radio)iodination, while preserving the affinity for the M₂ receptor, optimizing lipophilicity to allow optimal blood-brain-barrier (BBB) penetration and to limit nonspecific uptake, maintaining the size of the molecule as small as possible, while not compromising metabolic stability.

In an earlier study, our group evaluated the potential M₂ receptor tracer E-isodopentenyl-thio-TZTP, which showed moderate selectivity for the muscarinic M₂ receptor over the M₁ and M₃ receptors in vitro [25], although selectivity for M₂ receptors was less than the original FP-TZTP [10, 14]. However, in vivo experiments using the TZTP derivative proved to be unsuccessful due to high lipophilicity of the tracer and very rapid metabolism of the parent compound [10, 14]. The 6β-acetoxynortropane derivatives that were synthesized and evaluated in the present study have several advantages over the earlier tested TZTP derivative(s). The lipophilicity of derivative 5b and 5c or iodinated analogues of 10a and 10b is less than that of the earlier synthesized TZTPs, being within the estimated log P (P = partition coefficient in octanol-buffer at pH 7.4) range between 1 and 2 (data not shown), which is considered to be optimal for penetration of the BBB. Incorporation of an ester function such as in the 6β-4’-iodobenzoate ester of 6β-nortropinol (5c), 3β-phenyl-6β-acetoxynortropane (10a) or an additional hydroxyl group in 3α-hydroxy-3β-phenyl-6β-acetoxynortropane (10b) contributes to the reduction in lipophilicity as compared to the earlier reported TZTPs, which should theoretically limit nonspecific uptake of these potential tracers in the brain. Another advantage over the earlier tested TZTP derivatives is the position of the iodine atom. Although the previous TZTP derivatives also contained a sp2 carbon-bound iodine,
Competition on M₁ receptor subtype

(a)

Competition on M₂ receptor subtype

(c)

Competition on M₃ receptor subtype

(e)

Competition on M₂ receptor subtype

(d)

Competition on M₃ receptor subtype

(f)

- 6β-acetoxynortropane
- 6β-4′-iodobenzyl ether of 6β-nortropinol
- 6β-4′-iodobenzoate ester of 6β-nortropinol
- Atropine

**Figure 2:** Competition curves of 6β-acetoxynortropane (5a, $K_i$ for $M_2$ in two separate experiments 88.1 nM and 71.6 nM, resp.) and the 6β-4′-iodobenzyl ether (5b, $K_i$ for $M_2$ 3.0 μM) and 6β-4′-iodobenzoate ester (5c, $K_i$ for $M_2$ 6.8 μM) of 6β-nortropinol, 3β-phenyl-6β-acetoxynortropane ($10a$, $K_i$ for $M_2$ > 1 μM), and 3α-hydroxy-3β-phenyl-6β-acetoxynortropane ($10b$, $K_i$ for $M_2$ > 1 μM) to the binding of [³H]NMS to the muscarinic receptor subtypes M₁–M₃. In the curves of (a, c, e) (derivatives 5a, 5b, 5c), data are expressed as means ± SEM from 3 samples in a range of 1.0·10⁻¹⁰ M to 1.0·10⁻⁴ M of competitor concentrations. In the curves of (b, d, f) (derivatives 5a, 10a, 10b), data are expressed as means ± SEM from 4 samples in a range of 1.0·10⁻¹⁰ M to 1.0·10⁻⁵ M of competitor concentrations. Atropine curves are also displayed as a reference.

This was substituted on the alkenyl side chain, whereas in the present 6β-4′-iodobenzyl ether (5b) and 6β-iodobenzoate ester of 6β-nortropinol (5c), the iodine is bound to an aromatic sp² carbon atom, which favors the in vivo stability and prevents rapid deiodination. Although we did not test iodinated versions of 3β-phenyl-6β-acetoxynortropane ($10a$) and 3α-hydroxy-3β-phenyl-6β-acetoxynortropane ($10b$), the phenyl ring would also be the appropriate location for coupling of the iodine atom in these two compounds. Moreover, unlike the earlier described and apparently metabolically unstable TZTP derivatives [25], the 3β-phenyl-6β-acetoxynortropane ($10a$) and 3α-hydroxy-3β-phenyl-6β-
acetoxytropane \(10b\) should be more metabolically stable due to the direct substitution of the phenyl ring to the tropane skeleton, which is known to have favorable effects on the in vivo stability of tropane-derived radiotracers such as \[^{123}\text{I}]\text{FP-CIT} \[12, 31\] or \[^{123}\text{I}]\beta\text{-CIT} \[33\].

In our competitive binding experiments, the inhibition constant of the original compound 6β-acetoxytropane (5a) was substantially higher than the \(K_i\) that was described by Pei and coworkers \[27\]. Reasons for this may include differences in the reference tracer, which was \[^{3}\text{H}]\text{NMS}\) in the present experiments, whereas Pei et al. used \[^{3}\text{H}]\text{quinuclidinyl benzilate (QNB)}, as well as a difference between rat and human muscarinic receptors. Pei et al. demonstrated a \(K_i\) of 2.6 nM for 6β-acetoxytropane at the muscarinic M2 receptor and very high selectivity ratios over either M1 or M3 receptors using the tritiated antagonist. In the same study, an even lower inhibition constant was reported by Pei et al. when using the muscarinic agonist \[^{3}\text{H}]\text{oxtremorine} as a reference. In our study, using only \[^{3}\text{H}]\text{NMS} but not \[^{3}\text{H}]\text{oxtremorine} as a reference, we calculated \(K_i\) values to the M2 receptor of 71 and 88 nM, in two separate series of competitive binding experiments using different protocols, and lower selectivity ratios to M1 and M3 receptors of 65 and 70, respectively. Nevertheless, such selectivity ratios would be very adequate for imaging of muscarinic M2 receptors in vivo. However, the iodinated analogues that were tested (5b and 5c) only showed weak affinity for all three tested muscarinic receptor subtypes, whereas the \(K_i\) of either 3β-phenyl-6β-acetoxytropane (10a) or 3α-hydroxy-3β-phenyl-6β-acetoxytropane (10b) could not be assessed, but proved to be above the micromolar range. We tested the derivatives at a maximal concentration of \(10^{-5}\) M, which may be a limitation of the present study, but \(K_i\) values in the micromolar range or higher were not considered of interest for our purposes. However, it cannot be excluded that iodination of derivative 10a and 10b would result in improved affinities for muscarinic receptors. Also, substitution of the phenyl group at the 3α-position, which is known to have bulk tolerance in tropane-derived radiotracers (and muscarinic receptor antagonists such as atropine, NMS, and benztrapine), may improve the in vitro binding characteristics.

In conclusion, we synthesized a series of analogues to 6β-acetoxytropane, potentially being of interest for use as radiotracers for in vivo imaging of the muscarinic M2 receptor subtype in neurodegenerative or neuropsychiatric diseases. However, changing the original molecule on the 6β- or the 3αβ-position by substitution of a iodophenyl or phenyl ring severely reduced both the affinity and selectivity of the nortropane for the muscarinic M2 receptor subtype, and therefore, the synthesized analogues are not suitable for use in human SPECT imaging.

References

[1] D. C. Mash, D. D. Flynn, and L. T. Potter, “Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation,” Science, vol. 228, no. 4703, pp. 1115–1117, 1985.

[2] P. Tiraboschi, L. A. Hansen, M. Alford et al., “Cholinergic dysfunction in diseases with LEWY bodies,” Neurology, vol. 54, no. 2, pp. 407–411, 2000.

[3] D. S. Baskin, J. L. Browning, F. J. Pirozzolo, S. Korporaal, J. A. Baskin, and S. H. Appel, “Brain choline acetyltransferase and mental function in Alzheimer disease,” Archives of Neurology, vol. 56, no. 9, pp. 1121–1123, 1999.

[4] J. L. W. Bosboom, D. Stoffers, and E. C. Wolters, “Cognitive dysfunction and dementia in Parkinson’s disease,” Journal of Neural Transmission, vol. 111, no. 10–11, pp. 1303–1315, 2004.

[5] E. K. Perry, M. Curtis, and D. J. Dick, “Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 48, no. 5, pp. 413–421, 1985.

[6] J. M. Candy, R. H. Perry, and E. K. Perry, “Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases,” Journal of the Neurological Sciences, vol. 59, no. 2, pp. 277–289, 1983.

[7] J. T. Coyle, D. L. Price, and M. R. DeLong, “Alzheimer’s disease: a disorder of cortical cholinergic innervation,” Science, vol. 219, no. 4589, pp. 1184–1190, 1983.

[8] I. Aubert, D. M. Araujo, D. Cecyre, Y. Robitaille, S. Gauthier, and R. Quirion, “Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinson’s diseases,” Journal of Neurochemistry, vol. 58, no. 2, pp. 529–541, 1992.

[9] S. T. Rouse, S. M. Edmunds, H. Yi, M. L. Gilmor, and A. L. Levey, “Localization of M2 muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus,” Neurosci Letters, vol. 284, no. 3, pp. 182–186, 2000.

[10] D. O. Kiesewetter, J. Lee, L. Lang, S. G. Park, C. H. Paik, and W. C. Eckelman, “Preparation of 18F-labeled muscarinic agonist with M2 selectivity,” Journal of Medicinal Chemistry, vol. 38, no. 1, pp. 5–8, 1995.

[11] M. Maziere, “Cholinergic neurotransmission studied in vivo using positron emission tomography or single photon emission computerized tomography,” Pharmacology and Therapeutics, vol. 66, no. 1, pp. 83–101, 1995.

[12] D. W. McPherson, D. L. DeHaven-Hudkins, A. P. Callahan, and F. F. Knapp, “Synthesis and biodistribution of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl-[6α-hydroxy-(1-iodo-1-propan-3-yl)]-phenylacetate. A new ligand for the potential imaging of muscarinic receptors by single photon emission computed tomography,” Journal of Medicinal Chemistry, vol. 36, no. 7, pp. 848–854, 1993.

[13] D. O. Kiesewetter, R. E. Carson, E. M. Jagoda, P. Herscovitch, and W. C. Eckelman, “Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands,” Life Sciences, vol. 64, no. 6–7, pp. 511–518, 1999.

[14] P. Sauerberg, P. H. Olesen, S. Nielsen et al., “Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines,” Journal of Medicinal Chemistry, vol. 35, no. 12, pp. 2274–2283, 1992.

[15] L. Ravasi, D. O. Kiesewetter, K. Shimoji, G. Lucignani, and W. C. Eckelman, “Why does the agonist [18F]FP-TZTP bind preferentially to the M2 muscarinic receptor?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 3, pp. 292–300, 2006.

[16] R. M. Cohen, T. A. Podruchny, A. L. W. Bokde et al., “Higher in vivo muscarinic-2 receptor distribution volumes in aging
subjects with an apolipoprotein E-ε4 allele," Synapse, vol. 49, no. 3, pp. 150–156, 2003.

[17] T. A. Podruchny, C. Connolly, A. Bokde et al., “In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers,” Synapse, vol. 48, no. 1, pp. 39–44, 2003.

[18] D. M. Cannon, J. K. Klaver, S. K. Gandhi et al., “Genetic variation in cholinergic muscarinic-2 receptor gene modulates M receptor binding in vivo and accounts for reduced binding in bipolar disorder,” Molecular Psychiatry, vol. 16, pp. 407–418, 2010.

[19] J. Boooj, G. Tissingh, A. Winogrodzka, and E. A. Van Royen, “Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism,” European Journal of Nuclear Medicine, vol. 26, no. 2, pp. 171–182, 1999.

[20] M. H. Bourguignon, E. K. J. Pauwels, C. Loc’h, and B. Mazière, “Iodine-123 labelled radiopharmaceuticals and single-photon emission tomography: a natural liaison,” European Journal of Nuclear Medicine, vol. 24, no. 3, pp. 331–344, 1997.

[21] F. J. Diaz-Corrales, S. Sanz-Viedma, D. Garcia-Solis, T. Escobar-Delgado, and P. Mir, “Clinical features and I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 3, pp. 556–564, 2010.

[22] N. A. Lassen, “A reappraisal of the relative merits of SPET and PET in the quantitation of neurotransmitters: the advantage of a longer half-life,” European Journal of Nuclear Medicine, vol. 23, no. 1, pp. 1–4, 1996.

[23] S. A. Ross and J. P. Seibyl, “Research applications of selected 123I-labeled neuroreceptor SPECT imaging ligands,” Journal of Nuclear Medicine Technology, vol. 32, no. 4, pp. 209–214, 2004.

[24] S. Vallabhajosula, Molecular Imaging: Radiopharmaceuticals for PET and SPECT, Springer, Berlin, Germany, 2009.

[25] R. J. J. Knol, T. Doornbos, J. C. Van Den Bos et al., “Synthesis and evaluation of iodinated TZTP-derivatives as potential radioligands for imaging of muscarinic M receptors with SPET,” Nuclear Medicine and Biology, vol. 31, no. 1, pp. 111–123, 2004.

[26] K. Nobuhara, C. Halldin, H. Hall et al., “Z-IQNP: a potential radioligand for SPECT imaging of muscarinic acetylcholine receptors in Alzheimer’s disease,” Psychopharmacology, vol. 149, no. 1, pp. 45–55, 2000.

[27] X. F. Pei, T. H. Gupta, B. Radio, W. L. Padgeett, and J. W. Daly, "6β-acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M-receptors," Journal of Medicinal Chemistry, vol. 41, no. 12, pp. 2047–2055, 1998.

[28] R. Robinson, “A synthesis of tropinone,” Journal of the Chemical Society, Transactions, vol. 111, pp. 762–768, 1917.

[29] J. W. Boja, M. J. Kuhar, T. Kopajtic et al., “Secondary amine analogues of 3β-(4′-substituted phenyl)tropane-2β-carboxylic acid esters and N-norcocaine exhibit enhanced affinity for serotonin and norepinephrine transporters,” Journal of Medicinal Chemistry, vol. 37, no. 8, pp. 1220–1223, 1994.

[30] M. Koreeda and J. Luengo, “A new reagent for the selective, high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine,” Journal of Organic Chemistry, vol. 49, no. 11, pp. 2081–2082, 1984.

[31] J. Boooj, G. Andringa, L. J. M. Rijks et al., “[123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys,” Synapse, vol. 27, no. 3, pp. 183–190, 1997.

[32] J. L. Neumeyer, S. Wang, Y. Gao et al., “N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters,” Journal of Medicinal Chemistry, vol. 37, no. 1, pp. 1558–1561, 1994.

[33] S. Wang, Y. Gao, M. Laruelle et al., “Enantioselectivity of cocaine recognition sites: binding of (1S)- and (1R)-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT) to monoamine transporters,” Journal of Medicinal Chemistry, vol. 36, no. 13, pp. 1914–1917, 1993.
